{"id":658646,"date":"2023-07-07T07:46:01","date_gmt":"2023-07-07T07:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=658646"},"modified":"2023-07-07T07:46:01","modified_gmt":"2023-07-07T07:46:01","slug":"metastatic-colorectal-cancer-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-caribou-biosciences-intimia-biosciences-excision-biotherapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/metastatic-colorectal-cancer-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-caribou-biosciences-intimia-biosciences-excision-biotherapeutics_658646.html","title":{"rendered":"Metastatic Colorectal Cancer Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies &#8211; Caribou Biosciences, Intimia Biosciences, Excision Biotherapeutics"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Metastatic Colorectal Cancer Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies - Caribou Biosciences, Intimia Biosciences, Excision Biotherapeutics\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Metastatic Colorectal Cancer Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies - Caribou Biosciences, Intimia Biosciences, Excision Biotherapeutics\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the mCRC, historical and forecasted epidemiology as well as the mCRC market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-colorectal-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast-2032<\/a><\/strong>&#8221; report delivers an in-depth understanding of the mCRC, historical and forecasted epidemiology as well as the mCRC market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-colorectal-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Takeaways from the Metastatic Colorectal Cancer&nbsp;&nbsp;<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the past, 15 years ago, the median overall survival (MOS) was approximately 12 months, and the 5-year survival rate was 13%. However, the survival rate of these patients has increased, mainly due to the combined treatment of metastases with surgery and systemic therapy. Long-term survival or even cure can be attained in 20&ndash;50% of the patients who undergo complete R0 resection of liver or lung metastases, and around 70% 5-year survival of these patients can be achieved.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Metastatic Colorectal Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Metastatic CRC may consist of tumors identified at a distant site following a previously treated localized CRC (nonmetastatic or stage I-III) or may present de novo at stage IV, defined as metastatic disease or cancer that has spread outside the original colorectal mass.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/fb9198b614c70d8622ba7e4708528cff.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Discover more about the emerging Metastatic Colorectal Cancer&nbsp; drugs@ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-colorectal-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Metastatic Colorectal Cancer Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Metastatic Colorectal Cancer Key Companies&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Alexion Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">GlaxoSmithKline (GSK)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pfizer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Eli Lilly<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Taiho Oncology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bristol-Myers Squibb<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Amgen<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Metastatic Colorectal Cancer Therapies&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bevacizumab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Regorafenib<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Capecitabine<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Cyclophosphamide<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Capecitabine<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;BPI-421286<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=metastatic-colorectal-cancer-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-caribou-biosciences-intimia-biosciences-excision-biotherapeutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=metastatic-colorectal-cancer-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-caribou-biosciences-intimia-biosciences-excision-biotherapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the mCRC, historical and forecasted epidemiology as well as the mCRC market trends in the United States, EU5 (Germany, Spain, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/metastatic-colorectal-cancer-clinical-trials-a-drug-pipeline-analysis-report-2023-companies-caribou-biosciences-intimia-biosciences-excision-biotherapeutics_658646.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-658646","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/658646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=658646"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/658646\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=658646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=658646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=658646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}